Efficacy
death
RECURRENCE
At the time of data cutoff, 12.5% (66/526) of patients in the nivolumab group and 26.1% (69/264) of patients in the placebo group had recurrence or death, with an HR for RFS of 0.42 (95% CI: 0.30–0.59; 